Investors seeking long-term aggressive holdings need not look
beyond mutual funds betting on the technology sector. Even though
such funds experience relatively higher levels of volatility,
they tend to outperform other categories when markets as a whole
are seeing an uptrend. Recent results from tech firms have also
shown that the sector is gearing up to enter a new era of success
and prosperity. Further, fund prices are based on stronger
fundamentals compared to their initial boom period, substantially
reducing the risk involved.
Below we will share with you the 5 best performing healthcare
mutual funds year to date. To view the
Zacks Rank
and past performance of all healthcare funds, then
click here
.
|
Mutual Fund
|
Zacks Rank
|
Total Return YTD
|
|
ProFunds Biotech Ultra Sector
|
#1 Strong Buy
|
64.18%
|
|
Fidelity Select Biotechnology
|
#2 Buy
|
36.59%
|
|
Rydex Biotechnology
|
#4 Sell
|
36.54%
|
|
T. Rowe Price Health Sciences
|
#4 Sell
|
31.93%
|
|
VALIC Company I Health Sciences
|
#4 Sell
|
31.71%
|
ProFunds Biotechnology UltraSector
(BIPSX) invests in equity securities and derivatives that in the
opinion of the fund advisors possess daily return characteristics
identical to one and a half times the daily return of the Dow
Jones U.S. Biotechnology Index. The healthcare mutual fund is
non-diversified and has a three year annualized return of
22.93%.
The healthcare mutual fund has a minimum initial investment of
$15,000 and an expense ratio of 2.73% compared to a category
average of 1.52%.
Fidelity Select Biotechnology
(FBIOX) seeks capital growth. The fund invests the majority of
its assets in biotechnology companies as well as those seeking to
benefit from advances in the biotechnological sector. It focuses
on acquiring common stocks and may also purchases securities
issued by foreign companies. The healthcare mutual fund has a
three year annualized return of 21.61%.
Rajiv Kaul is the fund manager and has managed this healthcare
mutual fund since 2005.
Rydex Biotechnology
(RYOIX) utilises a large share of its assets to purchase equity
securities and derivatives issued by domestic biotechnology
companies. It focuses on acquiring securities of small and
mid-cap companies. The healthcare mutual fund has a three year
annualized return of 18.92%.
As of December 2012, this healthcare mutual fund held 46
issues, with 8.75% of its total assets invested in Amgen Inc.
T. Rowe Price Health Sciences
(PRHSX) seeks capital growth over the long term. The fund invests
heavily in common stocks of companies whose primary operations
are related to healthcare products medicine or life sciences. The
fund focuses on investing in large and mid-cap firms but may also
purchase stock of smaller companies. The healthcare mutual fund
has a three year annualized return of 19.43%.
The healthcare mutual fund has a minimum initial investment of
$2,500 and an expense ratio of 0.82% compared to a category
average of 1.52%.
VALIC Company I Health Sciences
(VCHSX) invests the majority of its assets in common stocks of
healthcare products, medicine or life sciences related companies.
It focuses mainly on investing in large and mid-cap companies.
Not more than 35% of its assets may be invested foreign
securities. The healthcare mutual fund has a three year
annualized return of 18.99%.
Kris H. Jenner is the fund manager and has managed this
healthcare mutual fund since 2000.
To view the Zacks Rank and past performance of all healthcare
mutual funds, then
click here
.
About Zacks Mutual Fund Rank
By applying the Zacks Rank to mutual funds, investors can find
funds that not only outpaced the market in the past but are also
expected to outperform going forward.
Learn more
about the
Zacks Mutual Fund Rank.
(BIPSX): ETF Research Reports
(FBIOX): ETF Research Reports
(PRHSX): ETF Research Reports
(RYOIX): ETF Research Reports
(VCHSX): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment
Research